FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant AAV expressing vectors, and can be used in medicine in treating a complement-related disease. Recombinant AAV vector with an expression cassette packed therein contains a nucleic acid encoding a human factor complement H (hfH) variant, functionally related to expression control sequences, which control its expression. Said version of hfH comprises a short consensus repeat (SCR) 1, 2, 3, 4, 19 and 20, and SCR 9, 10, 11, 12, 13, 14 and/or 15 are absent.
EFFECT: invention provides expressing a soluble variant of hfH protein preserving the complement regulation function.
17 cl, 37 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2017 |
|
RU2768982C2 |
| COMPOSITIONS AND METHODS OF TREATING MPS1 | 2014 |
|
RU2708318C2 |
| COMPLEMENT FACTOR I AND COMPLEMENT FACTOR I COFACTOR, VECTORS ENCODING THEM AND USE FOR THERAPEUTIC PURPOSES | 2019 |
|
RU2809247C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES, AND THEIR APPLICATION | 2017 |
|
RU2764919C2 |
| COMPOSITIONS, METHODS AND APPLICATIONS OF GENE TRANSFER FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2017 |
|
RU2805606C2 |
| GENE THERAPY OF OPHTHALMIC DISORDERS | 2016 |
|
RU2762747C2 |
